Prospects of Integrated Multi-Omics-Driven Biomarkers for Efficient Hair Loss Therapy from Systems Biology Perspective

The document discusses the global health problem of alopecia, or hair loss, which affects both men and women. It explains that hair loss can be caused by a variety of factors, including androgen-related problems, infections, stress, and genetic predisposition. The paper highlights the importance of understanding the hair growth cycle, which consists of the anagen (growth) phase, catagen (transitional) phase, and telogen (resting) phase. The most common types of non-scarring alopecia are androgenetic alopecia (AGA) and alopecia areata (AA). AGA, also known as male pattern baldness, affects approximately 50% of the world's adult population. AA, an autoimmune disease, affects nearly 2% of the world population. The paper emphasizes the need for novel and efficient hair loss therapies and discusses the potential of multi-omics level biomarkers and drug repositioning efforts for the treatment of AGA and AA. It also mentions that the global market size of alopecia was USD 2.6 billion in 2019 and is expected to increase in the coming years.